Click Holdings Limited (NASDAQ:CLIK) Short Interest Update

Click Holdings Limited (NASDAQ:CLIK) saw a large decline in short interest in July. As of July 15th, there was short interest totaling 1,939 shares, a decline of 94.9% from the June 30th total of 37,691 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 56,286 shares, the short-interest ratio is currently 0.0 days.

Click Stock Performance

NASDAQ CLIK traded up $0.03 during mid-day trading on Friday, hitting $1.63. The stock had a trading volume of 45,626 shares, compared to its average volume of 373,797. Click has a 52-week low of $1.32 and a 52-week high of $14.40. The company has a 50 day simple moving average of $1.57 and a 200 day simple moving average of $2.70.

Click (NASDAQ:CLIK) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $3.79 million for the quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CLIK shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a report on Wednesday, June 24th. Wall Street Zen raised shares of Click to a “hold” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Click presently has an average rating of “Sell”.

Institutional Investors Weigh In On Click

An institutional investor recently bought a new stake in Click stock. Renaissance Technologies LLC acquired a new stake in Click Holdings Limited (NASDAQ:CLIK) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click at the end of the most recent quarter.

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.